Whitehawk Therapeutics Inc

NASDAQ:WHWK

Biotechnology

Healthcare
$3.13 +1.42%

+$0.06 today

Market cap
$184.70M
Beta
0.77
P/E (TTM)
-2.6
EPS (TTM)
-$1.67
52W Low $1.57High $5.50

Volume 0.28M

Average 0.31M

WHWK Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Whitehawk Therapeutics IncNASDAQ: WHWK

Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025

Capital expenditures turns positive

Q4 FY2025 capital expenditures was $0, compared with -$186K a year earlier. Trailing-twelve-month capital expenditures was -$552K. Over 3 fiscal years it compounded at +7.5% a year.

Context

  • Capital expenditures amounted to 7.7% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$138K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
-$552K-66.6% YoY
LTMDec 2025
-$552K-66.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-66.6%——
3-year CAGR+7.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(552K) USD
Year-over-year change
+66.6%

Capital Expenditures vs competitors

How WHWK compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -66.6% is the 6th highest of 9, against a peer median of -31.9%.
  • Capital expenditures amounts to 7.7% of revenue for WHWK, versus a peer median of 1.1%.
WHWK Competitors
Capital Expenditures for WHWK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M USD-37.7%-19.2%1.1%
IMMXImmix Biopharma, Inc.LTM Mar 2026$697.7K USD-26.1%——
WHWKWhitehawk Therapeutics IncLTM Dec 2025$552K USD-66.6%+7.5%7.7%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$112K USD-95.7%-40.3%—
CLNNClene Inc.LTM Mar 2026$39K USD+874.9%-80.4%29.1%
CNTXContext Therapeutics Inc.LTM Mar 2026$37.26K USD-9.7%-60.2%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$34K USD-81.2%——
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$15.65K CAD-91.9%-46.9%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 USD+100.0%—0.0%
Peer median (excluding WHWK) —-31.9%-46.9%1.1%

Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Depreciation & Amortization105K159K169K193K79K
Deferred Income Tax00000
Stock-Based Compensation2.11M9.64M11.95M10.84M9.87M
Change in Working Capital3.96M(5.04M)(3.27M)3.72M1.93M
Accounts Receivables14.15M(1.86M)(3.63M)(415K)(1M)
Inventory0(1.86M)(3.27M)1.12M170K
Accounts Payables00003.92M
Other Working Capital(10.19M)(1.32M)3.62M3.02M(1.16M)
Other Non-Cash Items81.5M6.11M(2.75M)(10.61M)(78.77M)
Operating Cash Flow(22.42M)(49.64M)(59.66M)(59.55M)(97.43M)
Capital Expenditures(46K)(444K)(3.97M)(1.65M)(552K)
Acquisitions (Net)25.2M000101.29M
Purchases of Investments0(145.19M)(64.44M)(36.48M)(148.69M)
Sales of Investments012.75M151.62M63.34M59.85M
Other Investing Activities00000
Investing Cash Flow25.15M(132.89M)83.21M25.2M11.89M
Debt Repayment00000
Common Stock Issued155M72.5M0130K100M
Common Stock Repurchased00000
Dividends Paid(4.41M)0000
Other Financing Activities(8.78M)120K326K(16K)(5.63M)
Financing Cash Flow141.8M72.62M326K130K94.38M
Effect of Forex Changes000064K
Net Change in Cash144.53M(109.91M)23.87M(34.22M)8.9M
Free Cash Flow(22.47M)(50.08M)(63.64M)(61.2M)(97.99M)

Whitehawk Therapeutics Inc

NASDAQ:WHWK

Intrinsic Alpha fair value

Locked

Current Price

$3.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.